4:55 PM
 | 
Jul 24, 2014
 |  BC Extra  |  Financial News

Alexion reports 2Q14 earnings, EMA to review asfotase alfa

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) reported 2Q14 earnings that beat the Street on Thursday and separately said EMA accepted and granted accelerated assessment to an MAA for asfotase alfa to treat hypophosphatasia (HPP). The company expects to complete a rolling BLA submission for the product -- a fusion...

Read the full 219 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >